Aurora Breazna

944 total citations
20 papers, 482 citations indexed

About

Aurora Breazna is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pharmacology. According to data from OpenAlex, Aurora Breazna has authored 20 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Pharmacology. Recurrent topics in Aurora Breazna's work include Inflammatory mediators and NSAID effects (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer-related Molecular Pathways (4 papers). Aurora Breazna is often cited by papers focused on Inflammatory mediators and NSAID effects (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer-related Molecular Pathways (4 papers). Aurora Breazna collaborates with scholars based in United States, Hungary and Spain. Aurora Breazna's co-authors include George D. Demetri, Liviu Niculescu, Robert J. Motzer, Thomas Suter, Craig Eagle, Rebecca B. Rosenstein, Daniel J. Lenihan, Michael S. Ewer, Katalin Boér and Sophia Randolph and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

Aurora Breazna

20 papers receiving 461 citations

Peers

Countries citing papers authored by Aurora Breazna

Since Specialization

Citations

This map shows the geographic impact of Aurora Breazna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurora Breazna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurora Breazna more than expected).

Fields of papers citing papers by Aurora Breazna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurora Breazna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurora Breazna. The network helps show where Aurora Breazna may publish in the future.

Co-authorship network of co-authors of Aurora Breazna

This figure shows the co-authorship network connecting the top 25 collaborators of Aurora Breazna. A scholar is included among the top collaborators of Aurora Breazna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurora Breazna. Aurora Breazna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial. 2025 ·Journal of Clinical Oncology ·Morten Salomo, Enrique M. Ocio, Carmen Martínez‐Chamorro, Sosana Delimpasi, Albert Oriol, Meletios Α. Dimopoulos, (unknown), (unknown), Nisha S. Joseph, Mercedes Gironella, Rajshekhar Chakraborty, Carlos Fernández de Larrea, Aurora Breazna, (unknown), Anita Boyapati, Anasuya Hazra, Glenn S. Kroog, Shawn Sarkaria, Paula Rodríguez‐Otero	3
2	Efficacy and Safety of Olopatadine/Mometasone Combination Nasal Spray in Patients With Seasonal Allergic Rhinitis 2018 ·Journal of Allergy and Clinical Immunology ·Frank C. Hampel, Andrew Pedinoff, Robert L. Jacobs, Aurora Breazna, Cynthia Caracta, Sudeesh K. Tantry	2
3	Rapid Onset of Action on Nasal Symptoms and Ocular Symptom Improvement With Olopatadine/Mometasone Combination Nasal Spray in Patients With Seasonal Allergic Rhinitis 2018 ·Journal of Allergy and Clinical Immunology ·Gary Berman, Niran J. Amar, Craig LaForce, Aurora Breazna, Cynthia Caracta, Sudeesh K. Tantry	3
4	P434 Efficacy and safety of olopatadine/mometasone combination nasal spray for the treatment of seasonal allergic rhinitis 2017 ·Annals of Allergy Asthma & Immunology ·Paul H. Ratner, Frank C. Hampel, Aurora Breazna, Cynthia Caracta, (unknown)	3
5	A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors 2016 ·Cancer Chemotherapy and Pharmacology ·Justine Y. Bruce, Patricia LoRusso, Priscila Gonçalves, Elisabeth I. Heath, Elizabeth A. Sadowski, David R. Shalinsky, Yanwei Zhang, Anne M. Traynor, Aurora Breazna, Alejandro D. Ricart, Michael A. Tortorici, Glenn Liu	3
6	Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events 2014 ·European Journal of Cancer ·Michael S. Ewer, Thomas Suter, Daniel J. Lenihan, Liviu Niculescu, Aurora Breazna, George D. Demetri, Robert J. Motzer	73
7	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study 2013 ·Neuro-Oncology ·Jacques Grill, Birgit Geoerger, (unknown), Danuta Perek, Pierre Leblond, Adela Cañete, Isabelle Aerts, Luís Madero, (unknown), Joris Verlooy, Edward J. Estlin, Laura A. Cisar, Aurora Breazna, (unknown), Simon Bailey, Gary Nicolin, Richard G. Grundy, Darren Hargrave	29
8	A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study 2013 ·Journal of Neuro-Oncology ·Darren Hargrave, Birgit Geoerger, Didier Frappaz, Torsten Pietsch, (unknown), Laura A. Cisar, Aurora Breazna, (unknown), Ofelia Cruz, José Luís Fuster, Xavier Rialland, (unknown), Pierre Leblond, David M. Ashley, Giorgio Perilongo, Martin Elliott, Martin English, Niels Clausen, Jacques Grill	9
9	100O Results of A Randomized Phase 2 Study of Pd 0332991, A Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, In Combination with Letrozole vs Letrozole Alone For First-Line Treatment of ER + /Her2- Advanced Breast Cancer (Bc) 2012 ·Annals of Oncology ·Richard S. Finn, John Crown, Katalin Boér, István Láng, (unknown), Aurora Breazna, Steffan N. Ho, (unknown), Sophia Randolph, DJ Slamon	30
10	Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC) 2012 ·Cancer Research ·RS Finn, (unknown), István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravi Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, (unknown), (unknown), Aurora Breazna, Sung Tae Kim, Sophia Randolph, DJ Slamon	102
11	Treatment of Osteoarthritis with Continuous Versus Intermittent Celecoxib 2011 ·The Journal of Rheumatology ·Vibeke Strand, Lee S. Simon, Maxime Dougados, George H. Sands, Pritha Bhadra, Aurora Breazna, (unknown)	20
12	Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial 2011 ·The American Journal of Gastroenterology ·Nadir Arber, Julius Špičák, I Rácz, Miroslav Zavoral, Aurora Breazna, Paola Gerletti, María José Lechuga, (unknown), Rebecca B. Rosenstein, Craig Eagle, Bernard Levin	59
13	P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer. 2011 ·Cancer Research ·RS Finn, (unknown), Katalin Boér, István Láng, (unknown), Ravindranath Patel, Marcus Schmidt, Christopher Hagenstad, Howard J. Lim, Tamás Pintér, D. Amadori, David W. Chan, (unknown), Janice M. Walshe, Aurora Breazna, Sung Tae Kim, Sophia Randolph, DJ Slamon	3
14	Abstract A177: Phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of single agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors. 2011 ·Molecular Cancer Therapeutics ·Lee S. Rosen, Todd A. Blumenkopf, Aurora Breazna, (unknown), Jorge D. Gallo, Jonathan H. Goldman, Diane Wang, Linda Mileshkin, Sabine Eckhardt	10
15	Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·Linda Mileshkin, Lee S. Rosen, Todd A. Blumenkopf, Aurora Breazna, (unknown), James Davison, James M. Gallo, (unknown), (unknown), (unknown), S. Gail Eckhardt	6
16	Sunitinib (SU)-related hypertension in a randomized placebo (P)-controlled trial of GIST patients (pts). 2010 ·Journal of Clinical Oncology ·(unknown), Thomas Suter, (unknown), Liviu Niculescu, Aurora Breazna, Robert J. Motzer, G. D. Demetri	1
17	Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma 2009 ·Gastroenterology ·Andrew T. Chan, Ann G. Zauber, Meier Hsu, Aurora Breazna, David J. Hunter, Rebecca B. Rosenstein, Craig Eagle, Ernest T. Hawk, Monica M. Bertagnolli	41
18	A Novel Composite Endpoint to Evaluate the Gastrointestinal (GI) Effects of Nonsteroidal Antiinflammatory Drugs Through the Entire GI Tract 2009 ·The Journal of Rheumatology ·Francis K.L. Chan, Byron Cryer, Jay L. Goldstein, Fernando Laņas, David A. Peura, James M. Scheiman, Lee S. Simon, Gurkirpal Singh, Martin Stillman, C. Mel Wilcox, Manuela Berger, Aurora Breazna, William E. Dodge	61
19	Chemopreventive Effectiveness of Celecoxib Two Years After Cessation of Treatment 2008 ·Gastroenterology ·Nadir Arber, Julius Špičák, I Rácz, Miroslav Zavoral, María José Lechuga, Paola Gerletti, Rebecca B. Rosenstein, Craig Eagle, Bernard Levin, Aurora Breazna	1
20	Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST 2008 ·Journal of Clinical Oncology ·Peter Reichardt, Yubin Kang, (unknown), Beatrice Seddon, (unknown), Aurora Breazna, (unknown), George D. Demetri	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact